Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
Shots:
- Puma to receive upfront, milestones up to $7.2M and royalties on sales in Canada. Knight to get exclusive commercialization rights for Nerlynx and will also be responsible for its regulatory approvals in Canada
- In July, 2018 Puma has filled Nerlyn’s NDA to Health Canada for the treatment of early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy in adults
- Nerlynx (neratinib) is a tyrosine kinase inhibitor anticancer drug and has received the US FDA approval in July 2017, for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy in adults
Click here to read full press release/ article | Ref: Puma Biotechnology | Image: ValueWalk